Listing 3 - Actual negotiations

Indication:

For the treatment of Grade 2 WHO 2016, 2021 grading system astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.

Indication:

Multiple Sclerosis, Relapsing-Remitting

Indication:

Clostridioides difficile infection, prevention

Indication:

Insomnia

Indication:

For the treatment of adult patients with multiple myeloma, who have received 1 to 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.

Indication:

Multiple myeloma in adult patients who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and who are refractory to their last treatment

Indication:

Idiopathic pulmonary fibrosis and PF-ILD

Indication:

For the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC).

Indication:

Generalized pustular psoriasis (GPP)

Indication:

Non-small cell lung cancer (NSCLC), Locally advanced or metastatic, in adult patients with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on, or after platinum-based chemotherapy